Company news

Aurinia Pharmaceuticals Inc news in 2023

Aurinia Pharmaceuticals Inc's news releases, calls and decks from 2023, newest first.

View company

Aurinia Submits IND Application to US Food & Drug Administration for AUR 200

December 19, 2023

Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan

November 12, 2023

Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023

November 6, 2023

Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis

November 1, 2023

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results

November 1, 2023

Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis

October 25, 2023

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023

October 18, 2023

Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)

October 12, 2023

Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital

September 20, 2023

Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines

August 20, 2023

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results

August 2, 2023

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023

July 19, 2023

Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events

July 18, 2023

Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

June 28, 2023

Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy

June 19, 2023

LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone

May 31, 2023

Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees

May 25, 2023

Aurinia Announces 2023 Annual General Meeting Results

May 16, 2023

Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference

May 8, 2023

Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results

May 3, 2023

Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis

May 2, 2023

ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting

May 1, 2023

Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)

May 1, 2023

Glass Lewis Recommends Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual Meeting

April 27, 2023

Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys

April 24, 2023

Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023

April 23, 2023

Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office

April 10, 2023

Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial

April 4, 2023

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 2, 2023

Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates

February 27, 2023

Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference

February 23, 2023

Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023

February 6, 2023

Aurinia Announces PTAB Has Terminated Inter Partes Review

January 24, 2023

Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office

January 23, 2023

Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results

January 5, 2023

Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals

January 2, 2023

Calls in 2023

Decks in 2023